ERBB2 and breast cancer: Since pharmacological inhibition of Akt significantly delays acquired Ganetespib resistance, this establishes Akt as a unifying druggable node downstream of the widely activated HSP and RTK programs and suggests that Akt co-targeting together with Ganetespib may represent a therapeutically superior strategy for the treatment of HER2-positive breast cancer.